Abstract Library

#3895 NGS in G1-G2 pancreatic NETs – Data collection at University Hospital of Verona

Introduction: Pancreatic neuroendocrine tumors (pNETs) are known to have few druggable gene alterations. One possible area of interest concerns the possibility of giving better biological connotations to the >10% subgroup.

Conference:

Presenting Author: Borghesani M

Authors: Borghesani M, Mafficini A, Luchini C, Scarpa A, Milella M,

Keywords: NGS, neuroendocrine, pancreatic,

#2963 Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours

Introduction: Three molecular subtypes of pancreatic neuroendocrine tumours (PanNETs) have been described: insulinoma-like, intermediate and metastasis-like primary (MLP). The Latter is a non-functional tumours with highly metastatic potential. A mouse model of PanNET showed that MLP subtype has two different pathways of progression including stem/progenitor and epithelial-to-mesenchymal transition. However, the evolution of metastasis in patients requires further studies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Nyamundanda G, Ragulan C, Scarpa A,

Keywords: Pancreatic neuroendocrine tumors, metastasis, metastatic evolution, early metastasis, recurrence, prognosis, Patient tumours, cause and effect relationship, computational modeling, molecular subtypes, stages, metastatic potential,

#1706 Effectiveness of Chemoterapy in Advanced PanNETs with ki67<55%: Monocentric Experience

Introduction: Pancreatic Neuroendocrine Tumors (panNETs) are neoplasms with heterogeneous clinical behaviour. There is no standard treatment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Antista M, Cingarlini S, Grego E, Ortolani S, Scarpa A,

Keywords: chemotherapy, neuroendocrine, pan NETs, ki67<55%,

#858 Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?

Introduction: Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: davi' m

Authors: Davì M, Cingarlini S, Butturini G, Capelli P, Scarpa A,

Keywords: Everolimus, pancreatic NET, ectopic Cushing syndrome,

#650 Incidental Diagnosis as Prognostic Factor in Different Tumor-Stages of Non-Functioning Pancreatic Endocrine Tumors

Introduction: Although incidental diagnosis of non-functioning pancreatic endocrine tumors (NF-pNETs) is not an assurance of benign behavior, incidental NF-pNETs are associated with improved survival after resection.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Partelli S, Crippa S, Scarpa A, Zamboni G, Falconi M,

Keywords: incidental pancreatic neuroendocrine tumors,